SCHEMBL1605085

SCHEMBL1605085

NC1=NC(=O)C2=CC=NC2=N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7029229 0.67
SCHEMBL3266710 0.66
SCHEMBL4395748 0.62
SCHEMBL6272478 0.61
SCHEMBL15919003 0.58
SCHEMBL4721785 0.56
SCHEMBL14830503 0.56
SCHEMBL7569561 0.49
SCHEMBL7409317 0.49
SCHEMBL11769613 0.48

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110082158-A1 SELECTIVE PROTON COUPLED FOLATE TRANSPORTER AND FOLATE RECEPTOR, AND GARFTASE AND/OR OTHER FOLATE METABOLIZING ENZYMES INHIBITOR COMPOUNDS AND METHODS OF USING THE SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-04-07 US disclosed
US-6962920-B2 Pyrimidine derivatives and methods of making and using these derivatives DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) 2005-11-08 US disclosed
US-20040039000-A1 Novel pyrimidine derivatives and methods of making and using these derivatives GANGJEE ALEEM (US) 2004-02-26 US disclosed
US-6537999-B2 Furopyrimidines and pyrrolopyrimidines; treating cancer, and secondary infections caused by Pneumocystis carinii and Toxoplasmosis gondii in immunocompromised patients. DUQUESNE UNIVERSITY OF THE HOLY GHOST 2003-03-25 US disclosed
US-20020052384-A1 Novel pyrimidine derivatives and methods of making and using these derivatives GANGJEE ALEEM (US) 2002-05-02 US disclosed
US-6136601-A ADJUSTED NUCLEOTIDE SEQUENCES WHICH CAN BE UTILIZED FOR THE GENERATION OF PREFERENTIAL MUTATION EPOCH PHARMACEUTICALS, INC. (US) 2000-10-24 US disclosed
CN-1078235-A Medicinal compound LILLY CO ELI (US) 1993-11-10 CN disclosed
EP-0567223-A1 Glutamic acid derivatives as antineoplastic agents ELI LILLY AND COMPANY (US) 1993-10-27 EP disclosed
US-5196424-A Antitumor ELI LILLY AND COMPANY (US) 1993-03-23 US disclosed
EP-0119591-B1 THIODEAZAPURINE DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 1988-06-22 EP disclosed
EP-0089055-B1 DEAZAPURINE DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 1987-06-03 EP disclosed
US-4595530-A Thiodeazapurine derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1986-06-17 US disclosed
US-4571423-A Substituted 5-aminomethyl-2-acylaminopyrrolo[2,3-d]pyrimidin-4-ones TAKEDA CHEMICAL INDUSTRIES LTD. (JP) 1986-02-18 US disclosed
EP-0119591-A1 Thiodeazapurine derivatives Takeda Chemical Industries, Ltd. (JP) 1984-09-26 EP disclosed
EP-0089055-A2 Deazapurine derivatives Takeda Chemical Industries, Ltd. (JP) 1983-09-21 EP disclosed